neuropathy and hearing loss persisted throughout the study follow-up period, up to 30 months posttreatment. 21 These results suggest that adjuvant therapy improves survival at a cost of short-term decline in global QOL, which improves to a significant degree
Search Results
Survivorship in Non–Small Cell Lung Cancer: Challenges Faced and Steps Forward
Namrata Vijayvergia, Prashant C. Shah, and Crystal S. Denlinger
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan and Sara M. Tolaney
compared with chemotherapy alone in TNBC recurring within 1 year of adjuvant therapy. Table 2. Ongoing Anti–PD-1/L1 Combination and Novel Immunotherapy Trials in TNBC Early-Stage Chemotherapy Combination Regimens The combination of ICIs with chemotherapy in
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Featured Updates to the NCCN Guidelines
Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St. John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow
adjuvant therapy better. Omitting systemic therapy and administering RT alone is a category 2B option for patients with p16-positive cT0–2, cN0–1 disease (single node ≤3 cm) who have extranodal extension following surgery. For patients with positive or
Colon Cancer, Version 3.2014
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
-containing chemotherapeutic regimens are administered. 22 To limit the development of hepatotoxicity, it is therefore recommended that surgery be performed as soon as possible after the patient becomes resectable. Neoadjuvant and Adjuvant Therapy for Resectable
Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care
Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman
opportunities to further refine the current state of the art. Overdiagnosis occurs when tumors that would otherwise not become symptomatic are identified. Overtreatment occurs when such a tumor is treated, often with surgery and adjuvant therapy in the case of
Prostate Cancer, Version 1.2016
James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
diagnosed prostate cancer who are considering active surveillance, and in treated men who are considering adjuvant therapy or therapy for recurrences. Uncertainty about the risk of disease progression can be reduced if such molecular assays can accurately
Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma
Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison
were defined as having an RSI GES <0.3745 and RSI-high tumors as having an RSI GES ≥0.3745. Systemic Therapy Adjuvant therapy was delivered within 4 to 6 months of surgery and before recurrence at any site to 156 patients (38.0%), and included
Multimodality Approaches for the Curative Treatment of Esophageal Cancer
Raymond Jang, Gail Darling, and Rebecca K.S. Wong
adjuvant therapy. The patients were Japanese with SCC histology, and adjuvant therapy consisted of 2 cycles of cisplatin and fluorouracil. Recommendations: The Ontario guidelines panel recommended the use of preoperative platinumbased chemotherapy plus
Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts
Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson
determine whether cancer has recurred in some cancer types. Unfortunately, no tumor marker in breast cancer is accurate or leads to outcome improvements for women who have completed therapy with curative intent (eg adjuvant therapy) and are undergoing
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience
Emily C. Harrold, Ahmad F. Idris, Niamh M. Keegan, Lynda Corrigan, Min Yuen Teo, Martin O’Donnell, Sean Tee Lim, Eimear Duff, Dearbhaile M. O’Donnell, M. John Kennedy, Sue Sukor, Cliona Grant, David G. Gallagher, Sonya Collier, Tara Kingston, Ann Marie O’Dwyer, and Sinead Cuffe
have been identified up to 5 years after initiation of adjuvant therapy for cancer, and insomnia continues to remain a significant issue among long-term survivors (>5 years), 28 , 29 illustrating the chronicity of this sleep disturbance. Sleep
